Literatuur en richtlijnen

Literatuur

1. Van de Wetering et al. Controversies in the management of clinical stage I seminoma: carboplatin a decade in-time to start backing out J Clin Oncol. 2018 Mar 20; 36(9):837-840
2. Tandstad et al. One course of adjuvant BEP in clinical stage I nonseminoma mature and expanded results from the SWENOTECA group Ann Oncol. 2014 Nov; 25(11):2167-2172
3. De Wit et al. Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. J Clin Oncol. 2001 Mar 15; 19(6):1629-40
4. Hinton et al. Cisplatin, etoposide and either bleomycin or ifosfamide in the treatment of disseminated germ cell tumors: final analysis of an intergroup trial. Cancer 2003 Apr 15; 97(8):1869-75
5. Boormans JL et al. Prognostic factor risk groups for clinical stage I seminoma: an individual patient data analysis by the European Association of Urology testicular cancer guidelines panel and guidelines office. Eur Urol Oncol. 2024 Jun; 7(3):537-543

Richtlijnen

Ga naar de richtlijn Testicular cancer van de EAU. 

Ga naar de richtlijn Testicular seminoma and non-seminoma van de ESMO.